Property Summary

NCBI Gene PubMed Count 60
PubMed Score 315.42
PubTator Score 181.36

Knowledge Summary


No data available


  Disease Sources (4)

Disease Target Count P-value
pituitary cancer 1972 1.32846494402512E-11
osteosarcoma 7933 7.05132316978168E-10
nasopharyngeal carcinoma 1056 0.00105158942148782
interstitial cystitis 2299 0.00481516337922826
Disease Target Count Z-score Confidence
Cancer 2346 4.049 2.0
Agammaglobulinemia 24 3.387 1.7


  Differential Expression (4)

Disease log2 FC p
osteosarcoma -3.654 0.000
interstitial cystitis 1.900 0.005
nasopharyngeal carcinoma -1.600 0.001
pituitary cancer -3.600 0.000


Accession P40259 Q53FS2 Q9BU06
Symbols B29




  Ortholog (9)

 GWAS Trait (1)

Gene RIF (30)

26752547 MYD88 L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma.
25501023 Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
25414443 Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies.
25347427 Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system.
24769851 Phosphorylation of CD79a causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part.
24444466 CD79B and MYD88 mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease.
24253023 results suggest that MYD88 mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL
23649625 Data indicate a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription.
23361872 CD79B point mutation is associated with B-cell non-Hodgkin lymphomas.
22808296 The present study failed to find any mut-ation in MYD88, CARD11 or CD79B in ocular MALT lymphoma.

AA Sequence

VTLRTGEVKWSVGEHPGQE                                                       211 - 229

Text Mined References (66)

PMID Year Title
26752547 2016 Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
25501023 2014 Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
25416956 2014 A proteome-scale map of the human interactome network.
25414443 2015 Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.
25347427 2015 Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
24769851 2014 Tyrosine phosphorylation within the intrinsically disordered cytosolic domains of the B-cell receptor: an NMR-based structural analysis.
24444466 2014 CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
24253023 2014 High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
23649625 2013 Identification of a secondary promoter within the human B cell receptor component gene hCD79b.
23361872 2013 EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.